Yasir A W Skeiky

Summary

Affiliation: Aeras Global TB Vaccine Foundation
Country: USA

Publications

  1. ncbi Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen
    Yasir A W Skeiky
    Aeras Global TB Vaccine Foundation, Rockville, MD 20850, USA
    Vaccine 28:1084-93. 2010
  2. ncbi Advances in tuberculosis vaccine strategies
    Yasir A W Skeiky
    Aeras Global TB Vaccine Foundation, 1405 Research Blvd, Rockville, Maryland 20850, USA
    Nat Rev Microbiol 4:469-76. 2006
  3. ncbi Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis
    Ronggai Sun
    Aeras Global TB Vaccine Foundation, 1405 Research Blvd, Rockville, MD 20850, USA
    Vaccine 27:4412-23. 2009
  4. ncbi Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein
    Yasir A W Skeiky
    Corixa Corp, Seattle, WA 98104, USA
    J Immunol 172:7618-28. 2004
  5. ncbi Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
    Katarina Radosevic
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 75:4105-15. 2007
  6. ncbi Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis
    Liana Tsenova
    Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    Infect Immun 74:2392-401. 2006
  7. ncbi Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41
    Yasir A W Skeiky
    Corixa Corporation, Seattle, WA, USA
    Vaccine 23:3937-45. 2005
  8. ncbi The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs
    Lise Brandt
    Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins 80523, USA
    Infect Immun 72:6622-32. 2004
  9. ncbi Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design
    Johan Vekemans
    Medical Research Council Laboratories, Fajara, The Gambia
    Infect Immun 72:381-8. 2004
  10. ncbi Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 70:4215-25. 2002

Collaborators

Detail Information

Publications15

  1. ncbi Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen
    Yasir A W Skeiky
    Aeras Global TB Vaccine Foundation, Rockville, MD 20850, USA
    Vaccine 28:1084-93. 2010
    ..Therefore, all non-clinical data supports the suitability of HyVac4 as a safe, immunogenic, and effective vaccination in a prime-boost regimen with BCG...
  2. ncbi Advances in tuberculosis vaccine strategies
    Yasir A W Skeiky
    Aeras Global TB Vaccine Foundation, 1405 Research Blvd, Rockville, Maryland 20850, USA
    Nat Rev Microbiol 4:469-76. 2006
    ..This first generation of new vaccines might also complement drug treatment regimens and be effective against reactivation of TB from the latent state, which would significantly enhance their usefulness...
  3. ncbi Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis
    Ronggai Sun
    Aeras Global TB Vaccine Foundation, 1405 Research Blvd, Rockville, MD 20850, USA
    Vaccine 27:4412-23. 2009
    ..Thus, we have generated improved rBCG vaccine candidates that address many of the shortcomings of the currently licensed BCG vaccine strains...
  4. ncbi Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein
    Yasir A W Skeiky
    Corixa Corp, Seattle, WA 98104, USA
    J Immunol 172:7618-28. 2004
    ..tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans...
  5. ncbi Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
    Katarina Radosevic
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 75:4105-15. 2007
    ..These results unify conflicting reports on the relative importance of CD4 versus CD8 T-cell responses in protection and emphasize the key role of IFN-gamma...
  6. ncbi Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis
    Liana Tsenova
    Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    Infect Immun 74:2392-401. 2006
    ..Interestingly, Mtb72F+AS01B induced better protection against leukocytosis and weight loss, suggesting that the polyprotein in this adjuvant may boost immunity without exacerbating inflammation in previously BCG-vaccinated individuals...
  7. ncbi Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41
    Yasir A W Skeiky
    Corixa Corporation, Seattle, WA, USA
    Vaccine 23:3937-45. 2005
    ....
  8. ncbi The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs
    Lise Brandt
    Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins 80523, USA
    Infect Immun 72:6622-32. 2004
    ..Collectively, these data suggest that enhancing BCG is a valid vaccination strategy for tuberculosis that is worthy of clinical evaluation...
  9. ncbi Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design
    Johan Vekemans
    Medical Research Council Laboratories, Fajara, The Gambia
    Infect Immun 72:381-8. 2004
    ..While CFP-10 and alpha-crystallin are promising candidates for the immunodiagnosis of M. tuberculosis infection or for vaccine use, disease-associated immunosuppression may prevent IFN-gamma immunodiagnosis of more advanced tuberculosis...
  10. ncbi Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 70:4215-25. 2002
    ....
  11. ncbi A novel method for increasing the expression level of recombinant proteins
    Aijun Wang
    Department of Research and Development, Corixa Corporation, 1124 Columbia Street, Seattle, WA 98104, USA
    Protein Expr Purif 30:124-33. 2003
    ..Thus, this novel fusion expression system has become a powerful tool for many applications...
  12. ncbi Lipoarabinomannan-reactive human secretory immunoglobulin A responses induced by mucosal bacille Calmette-Guérin vaccination
    Robin M Brown
    Saint Louis University Vaccine and Treatment Evaluation Unit, Division of Infectious Diseases and Immunology, Department of Internal Medicine, Saint Louis University, St. Louis, Missouri 63110, USA
    J Infect Dis 187:513-7. 2003
    ..05). LAM-reactive antibody assays can serve as markers of humoral and mucosal immunity in future trials of BCG and newer attenuated mycobacterial vaccines...
  13. ncbi Variable expression of immunoreactive surface proteins of Propionibacterium acnes
    Michael J Lodes
    Corixa Corporation, Infectious Disease Research Institute, Seattle, WA 98101, USA
    Microbiology 152:3667-81. 2006
    ..In contrast, serum from acne-negative donors shows an IgG2 and IgG3 antibody subclass response to the carboxy-terminal region. These data have implications for the potential role of P. acnes in inflammatory acne and other diseases...
  14. ncbi Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant
    Yasir A W Skeiky
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
    Vaccine 20:3292-303. 2002
    ....
  15. ncbi Use of multiepitope polyproteins in serodiagnosis of active tuberculosis
    Raymond L Houghton
    Corixa Corporation, Seattle, Washington 98104, USA
    Clin Diagn Lab Immunol 9:883-91. 2002
    ..The data indicate that the use of multiple antigens, some of which are in a single polyprotein, can be used to facilitate the development of a highly sensitive test for M. tuberculosis antibody detection...